Eloxx Pharmaceuticals, Inc.
ELOX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ELOX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ELOX
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing its lead product candidate exaluren for the treatment of genetic disorders, with a history of net losses and an accumulated deficit of $304.3 million as of March 31, 2026 [sec].
Key risk: Going-concern risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 3 clinical trials for Eloxx Pharmaceuticals, Inc..
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing its lead product candidate exaluren for the treatment of genetic disorders, with a history of net losses and an accumulated deficit of $304.3 million as of March 31, 2026 [sec].
- Lead product candidate is exaluren, a potential treatment for genetic disorders [sec_mda · as of 2026-08-11].
- Net loss of $4.5M for the quarter ended June 30, 2026 [latest reported financials].
- Cash & equivalents of $62.0M as of June 30, 2026 [latest reported financials].
- Shareholders' equity was negative $27.9M as of June 30, 2026 [latest reported financials].
- Accumulated deficit of $304.3 million as of March 31, 2026 [sec · filed 2026-05-07].
What works
- Cash position of $62.0M as of June 30, 2026 provides near-term liquidity for ongoing operations [latest reported financials].
- Company is advancing exaluren through clinical development, indicating active pipeline progress [sec_mda · as of 2026-08-11].
- No debt on the balance sheet as of June 30, 2026 reduces financial risk [latest reported financials].
What to weigh
- Net loss of $4.5M for the quarter ended June 30, 2026 and accumulated deficit of $304.3M as of March 31, 2026 highlight ongoing unprofitability [latest reported financials] [sec · filed 2026-05-07].
- Negative shareholders' equity of $27.9M as of June 30, 2026 indicates liabilities exceed assets [latest reported financials].
- Company stated cash of $6.4M as of March 31, 2026 was not sufficient for 12 months of operations, raising going-concern risk [sec · filed 2026-05-07].
- Dependence on exaluren as the sole lead candidate creates single-product risk [sec · filed 2026-05-07].
From the filings
Quoted directly from source documents.
Accumulated deficit was $304.3 million as of March 31, 2026.
“As of March 31, 2026, we had an accumulated deficit of $304.3 million.”
SEC filings · May 7, 2026
Company depends on exaluren as its lead product candidate.
“our dependence on our lead product candidate, exaluren, and our ability to progress it through clinical trials”
SEC filings · May 7, 2026
Risks & what to watch (4)›
Key risks
- Going-concern risk — Cash of $6.4M as of March 31, 2026 was insufficient for 12 months of operations [sec · filed 2026-05-07].
- Single-product dependency — Company's future depends on exaluren, with no approved products or diversified pipeline [sec · filed 2026-05-07].
- Negative shareholders' equity — Shareholders' equity of -$27.9M as of June 30, 2026 indicates financial distress [latest reported financials].
- History of net losses — Net loss of $4.5M for Q2 2026 and accumulated deficit of $304.3M as of March 31, 2026 [latest reported financials] [sec · filed 2026-05-07].
What to watch
- Progress of exaluren clinical trials and any regulatory updates [sec_mda · as of 2026-08-11].
- Ability to secure additional financing to extend cash runway beyond current levels [sec · filed 2026-05-07].
- Any changes in cash position or net loss in future quarterly filings [latest reported financials].
- Potential uplisting of shares to Nasdaq Capital Market [sec · filed 2026-05-07].
Sources: SEC filings · SEC MD&A · Generated August 23, 2026 · How we verify sources →
Run Eloxx Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Eloxx Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
39.1 months
D/E 0.37 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Short Interest
as of May 1, 2026- % of float
- 0.8%
- Days to cover
- 0.7
- Shares short
- 21,485
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ELOX short interestFrequently asked questions
What is the AI investment thesis for Eloxx Pharmaceuticals, Inc.?
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing its lead product candidate exaluren for the treatment of genetic disorders, with a history of net losses and an accumulated deficit of $304.3 million as of March 31, 2026 [sec].
What is Eloxx Pharmaceuticals, Inc.'s lead drug candidate?
Eloxx Pharmaceuticals, Inc.'s most advanced tracked candidate is exaluren (Phase 2) for Alport Syndrome, X-Linked.
Who is the CEO of Eloxx Pharmaceuticals, Inc.?
Mr. Sumit Aggarwal M.B.A. is the chief executive officer of Eloxx Pharmaceuticals, Inc. (ELOX).
Where is Eloxx Pharmaceuticals, Inc. headquartered?
Eloxx Pharmaceuticals, Inc. (ELOX) is headquartered in Arlington, MA, United States.
What therapeutic areas does Eloxx Pharmaceuticals, Inc. focus on?
Eloxx Pharmaceuticals, Inc. develops therapies across Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.